VYNEVYNE Therapeutics Inc.

Nasdaq vynetherapeutics.com


$ 3.04 $ 0.18 (6.64 %)    

Tuesday, 07-May-2024 13:32:49 EDT
QQQ $ 440.32 $ 0.07 (0.02 %)
DIA $ 388.70 $ 0.29 (0.07 %)
SPY $ 517.26 $ 0.57 (0.11 %)
TLT $ 90.79 $ 0.55 (0.61 %)
GLD $ 214.23 $ -0.99 (-0.46 %)
$ 2.89
$ 2.73
$ 0.00 x 0
$ 0.00 x 0
$ 2.73 - $ 3.04
$ 1.67 - $ 8.73
120,101
na
29.69M
$ 0.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-01-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-14-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-04-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-03-2020 12-31-2019 10-K
18 10-31-2019 09-30-2019 10-Q
19 08-01-2019 06-30-2019 10-Q
20 05-02-2019 03-31-2019 10-Q
21 02-28-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-01-2018 06-30-2018 10-Q
24 05-09-2018 03-31-2018 10-Q
25 03-28-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

 vyne-therapeutics-presents-vyn201-at-2024-sid-annual-meeting

Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo

 hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

 vyne-therapeutics-q4-adjusted-eps-018-beats-050-estimate-sales-7600k-miss-15000k-estimate

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0...

 vyne-therapeutics-to-present-results-of-phase-1b-trial-for-vyn201-at-2024-global-vitiligo-foundation-annual-scientific-symposium

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201

 top-4-health-care-stocks-that-may-rocket-higher-in-q1

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

 why-richardson-electronics-shares-are-trading-lower-by-13-here-are-20-stocks-moving-premarket

Shares of Richardson Electronics, Ltd. (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted wea...

 vyne-therapeutics-announces-biomarker-data-from-phase-1b-trial-of-vyn201-for-treatment-of-vitiligo

VYN201 demonstrated positive effect on key biomarkers relevant to vitiligoData supports VYN201's rapid onset of action and ...

 vyne-therapeutics-q3-adj-eps-159-beats-197-estimate-sales-11400k-down-from-16700k-yoy

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(1.59) per share which beat the analyst consensus estimate of $(1...

 dow-surges-over-500-points-western-digital-announces-plan-to-split-into-two-companies

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday. The Dow ...

 hc-wainwright--co-maintains-buy-on-vyne-therapeutics-lowers-price-target-to-575

HC Wainwright & Co. analyst Joseph Pantginis maintains VYNE Therapeutics (NASDAQ:VYNE) with a Buy and lowers the price t...

 why-on-semiconductor-shares-are-trading-lower-by-around-18-here-are-other-stocks-moving-in-mondays-mid-day-session

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire...

 positive-momentum-for-vyne-therapeutics-psoriasis-rheumatoid-arthritis-candidate---analyst-expresses-encouragement

Earlier today, VYNE Therapeutics Inc (NASDAQ: VYNE) released new preclinical data showing the positive effect of its VYN202 in ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION